Shaare Zedek Medical Center

szmc.org.il

Total trials

193

Active

16

Phase 3

19

Total enrollment

42,689

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 10 of 10 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Chemotherapy Drugs, Cancer1
Vyxeos1
Mylotarg1
Naxitamab1
Nafarelin nasal spray1
Utrogestan®1
PEG 33501
Botulinum Toxin A1
Risankizumab1
Budesonide intervention1

Next readouts

  • 2021-04-15
  • 2026-10
  • 2027-03
  • 2027-07-01
  • 2028-06
  • 2028-09-07
  • 2029-05-01
  • 2030-09

Top conditions

  • Patent Ductus Arteriosus7
  • Cerebral Palsy6
  • ADHD4
  • Inflammatory Bowel Diseases4
  • Gaucher Disease, Type 14
  • Infertility4
  • Crohn's Disease4
  • Pregnancy4

Frequently asked questions about Shaare Zedek Medical Center

How many clinical trials does Shaare Zedek Medical Center have on ClinicalTrials.gov?
Shaare Zedek Medical Center is listed as the lead sponsor on 193 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
How many of Shaare Zedek Medical Center's trials are in Phase 3?
19 of Shaare Zedek Medical Center's trials are in Phase 3, spread across 10 active drug programs.
What therapeutic areas does Shaare Zedek Medical Center focus on?
Shaare Zedek Medical Center's most-studied conditions on ClinicalTrials.gov are Patent Ductus Arteriosus, Cerebral Palsy, ADHD, Inflammatory Bowel Diseases, Gaucher Disease, Type 1.
When are Shaare Zedek Medical Center's next clinical trial readouts?
Shaare Zedek Medical Center has 8 upcoming primary-completion readouts tracked here; the soonest is “Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer”, expected around 2021-04-15.